Literature DB >> 18310570

CATIE and CUtLASS: can we handle the truth?

Shôn Lewis, Jeffrey Lieberman.   

Abstract

Two large, non-commercial clinical trials comparing first- and second-generation antipsychotic drugs for people with chronic schizophrenia in the US and UK have shown unexpected results. In general, the newer drugs were no more effective or better tolerated than the older drugs. Clozapine outperformed other second-generation drugs. The implications are considered.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18310570     DOI： 10.1192/bjp.bp.107.037218

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  29 in total

Review 1.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

2.  First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia.

Authors:  Kjetil N Jørgensen; Ragnar Nesvåg; Sindre Gunleiksrud; Andrea Raballo; Erik G Jönsson; Ingrid Agartz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-07       Impact factor: 5.270

3.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Bringing a research base to psychiatry.

Authors:  Miriam Shuchman; Paul C Hébert; Rajendra Kale; Barbara Sibbald; Ken Flegel; Noni MacDonald
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

6.  The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface.

Authors:  Joseph M Schrader; Craig M Irving; J Christopher Octeau; Joseph A Christian; Timothy J Aballo; Dean J Kareemo; Joseph Conti; Jodi L Camberg; J Robert Lane; Jonathan A Javitch; Abraham Kovoor
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

7.  Changes in physician antipsychotic prescribing preferences, 2002-2007.

Authors:  Julie Donohue; A James O'Malley; Marcela Horvitz-Lennon; Anna Levine Taub; Ernst R Berndt; Haiden A Huskamp
Journal:  Psychiatr Serv       Date:  2014-03-01       Impact factor: 3.084

Review 8.  The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.

Authors:  C Cuerda; C Velasco; J Merchán-Naranjo; P García-Peris; C Arango
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

9.  Comparative effectiveness research for antipsychotic medications: how much is enough?

Authors:  David O Meltzer; Anirban Basu; Herbert Y Meltzer
Journal:  Health Aff (Millwood)       Date:  2009-07-21       Impact factor: 6.301

10.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.